Nuclear Chk1 prevents premature mitotic entry
Makoto Matsuyama1, Hidemasa Goto, Kousuke Kasahara
1Division of Biochemistry, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan. minagaki@aichi-cc.jp
Abstract:
Chk1 inhibits the premature activation of the cyclin-B1-Cdk1. However, it remains controversial whether Chk1 inhibits Cdk1 in the centrosome or in the nucleus before the G2-M transition. In this study, we examined the specificity of the mouse monoclonal anti-Chk1 antibody DCS-310, with which the centrosome was stained. Conditional Chk1 knockout in mouse embryonic fibroblasts reduced nuclear but not centrosomal staining with DCS-310. In Chk1(+/myc) human colon adenocarcinoma (DLD-1) cells, Chk1 was detected in the nucleus but not in the centrosome using an anti-Myc antibody. Through the combination of protein array and RNAi technologies, we identified Ccdc-151 as a protein that crossreacted with DCS-310 on the centrosome. Mitotic entry was delayed by expression of the Chk1 mutant that localized in the nucleus, although forced immobilization of Chk1 to the centrosome had little impact on the timing of mitotic entry. These results suggest that nuclear but not centrosomal Chk1 contributes to correct timing of mitotic entry.
Insights
Nuclear Chk1 (Checkpoint kinase 1) regulates the timing of mitotic entry, while centrosomal staining was found to be a false positive. This clarifies Chk1
Area of Science:
- Cell cycle regulation
- Molecular biology
- Cancer research
Background:
- Checkpoint kinase 1 (Chk1) is known to inhibit cyclin-B1-Cdk1 activation, preventing premature mitosis.
- The precise location where Chk1 exerts its inhibitory function (nucleus or centrosome) before the G2-M transition is debated.
Purpose of the Study:
- To investigate the specific role of Chk1 localization in regulating the timing of mitotic entry.
- To determine whether Chk1 functions in the nucleus or centrosome before the G2-M transition.
Main Methods:
- Utilized a specific anti-Chk1 antibody (DCS-310) and conditional Chk1 knockout mouse embryonic fibroblasts.
- Employed anti-Myc antibody in Chk1(+/myc) human colon adenocarcinoma (DLD-1) cells.
- Combined protein array and RNAi technologies to identify cross-reacting proteins.
- Generated Chk1 mutants with altered subcellular localization (nuclear vs. centrosomal).
Main Results:
- The anti-Chk1 antibody DCS-310 showed cross-reactivity with Ccdc-151 at the centrosome.
- Conditional Chk1 knockout reduced nuclear staining but not centrosomal staining with DCS-310.
- Chk1 was detected in the nucleus, not the centrosome, in DLD-1 cells.
- Nuclear Chk1 localization delayed mitotic entry, whereas centrosomal Chk1 had minimal impact.
Conclusions:
- Nuclear Chk1, not centrosomal Chk1, is crucial for the correct timing of mitotic entry.
- The anti-Chk1 antibody DCS-310 can lead to misinterpretation of Chk1 localization at the centrosome due to cross-reactivity.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity


